Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project

作者信息Yangyupei Yang, Maria Deloria Knoll, Carly Herbert, Julia C Bennett, Daniel R Feikin, Maria Garcia Quesada, Marissa K Hetrich, Scott L Zeger, Eunice W Kagucia, Melody Xiao, Adam L Cohen, Mark van der Linden, Mignon du Plessis, Inci Yildirim, Brita A Winje, Emmanuelle Varon, Maria Teresa Valenzuela, Palle Valentiner-Branth, Anneke Steens, J Anthony Scott, Larisa Savrasova, Juan Carlos Sanz, Aalisha Sahu Khan, Kazunori Oishi, Néhémie Nzoyikorera, J Pekka Nuorti, Jolita Mereckiene, Kimberley McMahon, Allison McGeer, Grant A Mackenzie, Laura MacDonald, Shamez N Ladhani, Karl G Kristinsson, Jackie Kleynhans, James D Kellner, Sanjay Jayasinghe, Pak-Leung Ho, Markus Hilty, Laura L Hammitt, Marcela Guevara, Charlotte Gilkison, Ryan Gierke, Stefanie Desmet, Philippe De Wals, Ron Dagan, Edoardo Colzani, Pilar Ciruela, Urtnasan Chuluunbat, Guanhao Chan, Romina Camilli, Michael G Bruce, Maria-Cristina C Brandileone, Krow Ampofo, Katherine L O'Brien, Kyla Hayford, PSERENADE Team
PMID39864526
期刊J Infect
发布时间2025-03
DOI10.1016/j.jinf.2025.106426

摘要

Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally. Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally. Site-specific meningitis incidence rate ratios (IRRs) comparing pre-PCV incidence to each year post-PCV10/13 were estimated by age (<5, 5-17 and ≥18 years) using Bayesian multi-level mixed effects Poisson regression, accounting for pre-PCV trends. All-site weighted average IRRs were estimated using linear mixed-effects regression stratified by age, product (PCV10 or PCV13) and prior PCV7 impact (none, moderate, or substantial). Changes in pneumococcal meningitis incidence were estimated overall and for product-specific vaccine-types and non-PCV13-types. Results: Analyses included 10,168 cases <5 y from PCV13 sites and 2849 from PCV10 sites, 3711 and 1549 for 5-17 y and 29,187 and 5653 for ≥18 y from 42 surveillance sites (30 PCV13, 12 PCV10, 2 PCV10/13) in 30 countries, primarily high-income (84%). Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 48-74% across products and PCV7 impact strata for children <5 y, 35-62% for 5-17 y and 0-36% for ≥18 y. Impact against PCV10-types at PCV10 sites, and PCV13-types at PCV13 sites was high for all age groups (<5 y: 96-100%; 5-17 y: 77-85%; ≥18 y: 73-85%). After switching from PCV7 to PCV10/13, increases in non-PCV13-types were generally low to none for all age groups. Conclusion: Pneumococcal meningitis declined in all age groups following PCV10/PCV13 introduction. Plateaus in non-PCV13-type meningitis suggest less replacement than for all IPD. Data from meningitis belt and high-burden settings were limited.

实验方法